| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.84 | 0.002 | 0.849 | Acetylcholine antagonist | 0.849 0.002 DBMET00746 | DBMET00746 | |
| 0.838 | 0.002 | 0.848 | Cholinergic antagonist | 0.848 0.002 DBMET00746 | DBMET00746 | |
| 0.771 | 0.002 | 0.795 | Acetylcholine muscarinic antagonist | 0.795 0.002 DBMET00746 | DBMET00746 | |
| 0.769 | 0.005 | 0.769 | Toll-Like receptor 7 agonist | 0.733 0.007 DBMET00746 | ||
| 0.759 | 0.002 | 0.759 | Acetylcholine M1 receptor antagonist | 0.727 0.003 DBMET00746 | ||
| 0.76 | 0.005 | 0.76 | Toll-Like receptor agonist | 0.723 0.008 DBMET00746 | ||
| 0.699 | 0.003 | 0.699 | Acetylcholine nicotinic antagonist | 0.534 0.004 DBMET00746 | ||
| 0.696 | 0.002 | 0.696 | Acetylcholine M2 receptor antagonist | 0.602 0.003 DBMET00746 | ||
| 0.683 | 0.004 | 0.683 | Cholinergic | 0.596 0.005 DBMET00746 | ||
| 0.662 | 0.003 | 0.662 | Acetylcholine agonist | 0.442 0.004 DBMET00746 | ||
| 0.647 | 0.003 | 0.647 | Neuronal nicotinic receptor antagonist | 0.412 0.004 DBMET00746 | ||
| 0.638 | 0.002 | 0.684 | Acetylcholine M3 receptor antagonist | 0.684 0.002 DBMET00746 | DBMET00746 | |
| 0.636 | 0.021 | 0.636 | Analgesic | 0.633 0.021 DBMET00746 | ||
| 0.567 | 0.013 | 0.567 | Nootropic | 0.413 0.035 DBMET00746 | ||
| 0.556 | 0.002 | 0.556 | Nicotinic receptor alpha7 subunit antagonist | 0.386 0.003 DBMET00746 | ||
| 0.53 | 0.002 | 0.53 | Acetylcholine muscarinic agonist | 0.392 0.003 DBMET00746 | ||
| 0.524 | 0.002 | 0.524 | Acetylcholine M1 receptor agonist | 0.34 0.003 DBMET00746 | ||
| 0.496 | 0.038 | 0.496 | Antiobesity | 0.33 0.098 DBMET00746 | ||
| 0.46 | 0.003 | 0.46 | 5 Hydroxytryptamine 3 antagonist | 0.182 0.007 DBMET00746 | ||
| 0.467 | 0.033 | 0.467 | 5 Hydroxytryptamine release stimulant | 0.192 0.128 DBMET00746 | ||
| 0.454 | 0.03 | 0.521 | Spasmolytic | 0.521 0.02 DBMET00746 | DBMET00746 | |
| 0.402 | 0.003 | 0.402 | Acetylcholine nicotinic agonist | 0.201 0.008 DBMET00746 | ||
| 0.378 | 0.001 | 0.378 | Acetylcholine M4 receptor agonist | 0.238 0.002 DBMET00746 | ||
| 0.337 | 0.003 | 0.337 | Nicotinic neuronal receptor agonist | 0.125 0.008 DBMET00746 | ||
| 0.338 | 0.007 | 0.338 | Bronchodilator | 0.3 0.009 DBMET00746 | ||
| 0.253 | 0.003 | 0.253 | Nicotinic alpha7 receptor agonist | 0.106 0.009 DBMET00746 | ||
| 0.269 | 0.022 | 0.269 | 5 Hydroxytryptamine antagonist | 0.101 0.078 DBMET00746 | ||
| 0.244 | 0.003 | 0.244 | 5 Hydroxytryptamine 3B antagonist | 0.068 0.009 DBMET00746 | ||
| 0.242 | 0.008 | 0.242 | Nav1.5 sodium channel blocker | 0.116 0.06 DBMET00746 | ||
| 0.278 | 0.055 | 0.278 | HERG channel blocker | |||
| 0.233 | 0.016 | 0.233 | Antihistaminic | 0.095 0.059 DBMET00746 | ||
| 0.221 | 0.004 | 0.221 | Acetylcholine M3 receptor agonist | 0.201 0.004 DBMET00746 | ||
| 0.23 | 0.015 | 0.23 | Histamine antagonist | 0.085 0.059 DBMET00746 | ||
| 0.271 | 0.059 | 0.271 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.26 | 0.055 | 0.312 | Psychostimulant | 0.312 0.04 DBMET00746 | DBMET00746 | |
| 0.202 | 0.005 | 0.202 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitor | 0.16 0.005 DBMET00746 | ||
| 0.2 | 0.004 | 0.2 | Acetylcholine M2 receptor agonist | 0.148 0.004 DBMET00746 | ||
| 0.259 | 0.063 | 0.259 | Hypolipemic | 0.232 0.076 DBMET00746 | ||
| 0.331 | 0.137 | 0.348 | Cyclophilin D inhibitor | 0.348 0.123 DBMET00746 | DBMET00746 | |
| 0.196 | 0.015 | 0.196 | Antineoplastic alkaloid | 0.181 0.019 DBMET00746 | ||
| 0.18 | 0.007 | 0.18 | Dopamine uptake inhibitor | 0.148 0.01 DBMET00746 | ||
| 0.169 | 0.008 | 0.169 | Acetylcholine M4 receptor antagonist | 0.083 0.043 DBMET00746 | ||
| 0.164 | 0.004 | 0.164 | Acetylcholine M5 receptor agonist | 0.115 0.013 DBMET00746 | ||
| 0.151 | 0.005 | 0.151 | Neurokinin 1 antagonist | 0.1 0.006 DBMET00746 | ||
| 0.144 | 0.004 | 0.144 | Complement C5a chemotactic receptor antagonist | 0.035 0.015 DBMET00746 | ||
| 0.148 | 0.008 | 0.148 | Nicotinic alpha4beta2 receptor antagonist | 0.101 0.03 DBMET00746 | ||
| 0.179 | 0.04 | 0.179 | Calcium channel blocker | 0.163 0.049 DBMET00746 | ||
| 0.14 | 0.005 | 0.14 | Neurokinin antagonist | 0.094 0.013 DBMET00746 | ||
| 0.142 | 0.011 | 0.142 | Calcium channel L-type blocker | 0.093 0.029 DBMET00746 | ||
| 0.132 | 0.004 | 0.132 | ADAM10 endopeptidase inhibitor | 0.085 0.005 DBMET00746 | ||
| 0.132 | 0.01 | 0.132 | Acetylcholine M5 receptor antagonist | 0.065 0.036 DBMET00746 | ||
| 0.124 | 0.008 | 0.124 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.203 | 0.091 | 0.203 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.111 | 0.005 | 0.111 | 5 Hydroxytryptamine 4 antagonist | 0.08 0.013 DBMET00746 | ||
| 0.178 | 0.074 | 0.179 | Amyloid beta precursor protein antagonist | 0.179 0.073 DBMET00746 | DBMET00746 | |
| 0.211 | 0.109 | 0.211 | Cardiotonic | |||
| 0.107 | 0.009 | 0.107 | Nicotinic receptor alpha3 subunit antagonist | 0.052 0.024 DBMET00746 | ||
| 0.163 | 0.077 | 0.163 | Sigma receptor agonist | 0.125 0.108 DBMET00746 | ||
| 0.097 | 0.013 | 0.097 | Histamine H3 receptor antagonist | |||
| 0.087 | 0.007 | 0.087 | G protein-coupled receptor agonist | 0.035 0.029 DBMET00746 | ||
| 0.084 | 0.007 | 0.084 | Substance P antagonist | 0.06 0.012 DBMET00746 | ||
| 0.082 | 0.005 | 0.082 | Glucose-dependent insulinotropic receptor agonist | 0.034 0.025 DBMET00746 | ||
| 0.115 | 0.042 | 0.115 | Prolactin inhibitor | |||
| 0.093 | 0.021 | 0.093 | Adrenaline uptake inhibitor | 0.093 0.021 DBMET00746 | ||
| 0.079 | 0.011 | 0.079 | Kinesin-like protein 1 inhibitor | 0.033 0.031 DBMET00746 | ||
| 0.079 | 0.011 | 0.079 | Kinesin antagonist | 0.033 0.031 DBMET00746 | ||
| 0.121 | 0.055 | 0.121 | Calcium channel (voltage-sensitive) blocker | 0.106 0.075 DBMET00746 | ||
| 0.077 | 0.014 | 0.077 | Nicotinic receptor alpha4 subunit antagonist | 0.06 0.022 DBMET00746 | ||
| 0.059 | 0.004 | 0.059 | Nicotinic alpha3beta4 receptor agonist | 0.034 0.015 DBMET00746 | ||
| 0.073 | 0.018 | 0.073 | Prolactin release inhibitor | 0.073 0.018 DBMET00746 | ||
| 0.086 | 0.032 | 0.086 | Toll-Like receptor 7 antagonist | |||
| 0.174 | 0.122 | 0.174 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.131 | 0.079 | 0.131 | Neurotrophic factor | |||
| 0.058 | 0.009 | 0.058 | Tryptase inhibitor | 0.045 0.016 DBMET00746 | ||
| 0.065 | 0.016 | 0.069 | Opioid kappa receptor agonist | 0.069 0.015 DBMET00746 | DBMET00746 | |
| 0.059 | 0.013 | 0.059 | Guanylate cyclase inhibitor | |||
| 0.114 | 0.068 | 0.134 | Microtubule formation inhibitor | 0.134 0.047 DBMET00746 | DBMET00746 | |
| 0.06 | 0.017 | 0.06 | Cholesterol esterase inhibitor | |||
| 0.063 | 0.021 | 0.063 | Glucose-6-phosphate translocase inhibitor | 0.056 0.029 DBMET00746 | ||
| 0.052 | 0.01 | 0.052 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.044 0.016 DBMET00746 | ||
| 0.159 | 0.118 | 0.159 | Anticonvulsant | |||
| 0.108 | 0.067 | 0.108 | 5 Hydroxytryptamine 3A agonist | |||
| 0.197 | 0.158 | 0.197 | 5 Hydroxytryptamine uptake stimulant | |||
| 0.059 | 0.02 | 0.059 | Dopamine D5 antagonist | |||
| 0.191 | 0.153 | 0.191 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.05 | 0.014 | 0.05 | Squalene synthetase inhibitor | 0.05 0.014 DBMET00746 | ||
| 0.134 | 0.1 | 0.135 | Ca2+-transporting ATPase inhibitor | 0.135 0.093 DBMET00746 | DBMET00746 | |
| 0.059 | 0.027 | 0.059 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.07 | 0.04 | 0.07 | Dopamine D1 antagonist | |||
| 0.073 | 0.045 | 0.073 | 5 Hydroxytryptamine agonist | |||
| 0.089 | 0.065 | 0.089 | HIV-1 integrase (Overall Integration) inhibitor | |||
| 0.073 | 0.049 | 0.073 | Glycine receptor agonist | 0.068 0.06 DBMET00746 | ||
| 0.082 | 0.059 | 0.082 | Phosphodiesterase IV inhibitor | |||
| 0.043 | 0.022 | 0.043 | Vascular adhesion protein 1 inhibitor | |||
| 0.082 | 0.065 | 0.082 | Vanilloid agonist | |||
| 0.049 | 0.033 | 0.049 | HCV NS3/NS4A protease inhibitor | |||
| 0.108 | 0.095 | 0.108 | Phosphodiesterase inhibitor | |||
| 0.036 | 0.024 | 0.046 | Ceramide glucosyltransferase inhibitor | 0.046 0.01 DBMET00746 | DBMET00746 | |
| 0.015 | 0.004 | 0.015 | Glucose-dependent insulinotropic receptor antagonist | 0.012 0.008 DBMET00746 | ||
| 0.025 | 0.014 | 0.025 | 5 Hydroxytryptamine 4 agonist | |||
| 0.052 | 0.042 | 0.052 | CC chemokine 2 receptor antagonist | |||
| 0.029 | 0.019 | 0.029 | Nicotinic alpha4beta2 receptor agonist | |||
| 0.048 | 0.039 | 0.048 | CC chemokine 5 receptor antagonist | |||
| 0.057 | 0.049 | 0.057 | NMDA 2C receptor antagonist | |||
| 0.078 | 0.071 | 0.078 | CC chemokine 5 receptor agonist | |||
| 0.022 | 0.016 | 0.022 | Dopamine D1 agonist | |||
| 0.044 | 0.039 | 0.047 | Dopamine transporter inhibitor | 0.047 0.035 DBMET00746 | DBMET00746 | |
| 0.103 | 0.098 | 0.149 | Alpha-N-acetylglucosaminidase inhibitor | 0.149 0.056 DBMET00746 | DBMET00746 | |
| 0.073 | 0.069 | 0.073 | Opioid kappa receptor antagonist | |||
| 0.022 | 0.02 | 0.022 | Calcitonin gene-related peptide antagonist | |||
| 0.054 | 0.052 | 0.054 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.07 | 0.069 | 0.07 | Histamine H1 receptor antagonist | |||
| 0.041 | 0.04 | 0.041 | Sigma receptor antagonist | |||
| 0.03 | 0.059 | 0.088 | Acetyl-CoA carboxylase inhibitor | 0.088 0.006 DBMET00746 | DBMET00746 | |
| 0.009 | 0.05 | 0.058 | Acetyl-CoA carboxylase 2 inhibitor | 0.058 0.005 DBMET00746 | DBMET00746 | |
| 0.036 | 0.085 | 0.115 | NMDA 2B receptor antagonist | 0.115 0.012 DBMET00746 | DBMET00746 | |
| 0.034 | 0.093 | 0.058 | Alpha-mannosidase inhibitor | 0.058 0.029 DBMET00746 | DBMET00746 | |
| 0.021 | 0.112 | 0.042 | Mannosidase inhibitor | 0.042 0.036 DBMET00746 | DBMET00746 | |
| 0.159 | 0.251 | 0.2 | Sodium/bile acid cotransporter inhibitor | 0.2 0.188 DBMET00746 | DBMET00746 | |
| 0.032 | 0.197 | 0.331 | Ca(v)3.2 blocker | 0.331 0.003 DBMET00746 | DBMET00746 | |
| 0.062 | 0.31 | 0.155 | Nitric oxide antagonist | 0.155 0.091 DBMET00746 | DBMET00746 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |